Kornimate/medical-research-clean huggingface dataset:
predictive value of epicardial adipose tissue for pulmonary embolism and death in patients with lung cancer

Conditions: Pulmonary Embolism; Lung Cancer

Summary: the occurrence and progression of lung cancer is related to visceral adipose tissue (vat). epicardial adipose tissue (eat) is a kind of vat, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. however, in lung cancer patients, the clinical correlation between eat and pulmonary embolism has not been reported. objective: to analyze the risk factors of poor prognosis in lung cancer patients with pe, and to explore the predictive value of eat in pulmonary embolism events and death in lung cancer patients. methods: eat volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. the incidence of adverse prognosis and related factors were followed up by telephone.


Eligibility criteria:
inclusion criteria: * the pathological diagnosis was lung cancer * pulmonary artery was evaluated by cta during hospitalization. exclusion criteria: * patients with incomplete clinical data * patients with no follow-up data * patients with a history of pe before diagnosis of lung cancer
covid-19 infection and multiple myeloma

Conditions: Multiple Myeloma; Covid19; Corona Virus Infection

Summary: collect in an observational study the outcomes of covid19 infection in mm patients across europe.

coronavirus disease 2019 (covid-19), caused by a novel coronavirus (sars-cov-2), is a highly contagious disease that appeared in wuhan, hubei province of china in december 2019. it has now spread to multiple countries through infected persons travelling mainly by air. most of the infected patients have mild symptoms including fever, fatigue and cough. but in severe cases, patients can progress rapidly and develop the acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulopathy including a disseminated intravascular coagulation (dic). multiple myeloma (mm) is a mature b-cell malignancy largely affecting the older patient with a median age at presentation of 70 years. the general performance status (ps) and the presence of comorbidity can identify a group of patients with poor tolerance to treatment, as well as risks of both bacterial and viral infection. mm patients have benefited significantly from therapeutic developments, however, the host response biology of the older person, coupled with a distinct disease biology overlay induces immune dysfunction. for example, the impact of aging on the human immune system is well documented. in mm it has long-since been understood that there is a spectrum of immune dysregulation, an important host factor considered in the "hallmarks of cancer" theory. in addition, the delivery of anti-mm therapy includes immune modulating agents such as steroids, proteasome inhibitors and cd38-directed therapy though not all immune modulation is necessarily detrimental. as such, myeloma patients are considered a higher risk in the current pandemic with sars-covid19. however, it is not clear whether this is actually the case, and the risk may not be different to population in general. equally it may be sub-groups of patients who are at risk e.g. on treatment versus stable response (plateau), frailty. as such, this proposal aims to collect in an observational study, the outcomes of covid19 infection in mm patients across europe.

Eligibility criteria:
inclusion criteria: * multiple myeloma patients * covid-19 infection
transcutaneous spinal cord stimulation to promote walking recovery after spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the goal of this clinical trial is to investigate the effects of transcutaneous spinal cord stimulation (tscs) combined with exoskeleton training, as compared to exoskeleton training alone to improve motor function in individuals with incomplete spinal cord injury who are 12 months or less post-injury. participants will be randomly assigned to a treatment group (exoskeleton training with tscs, or exoskeleton training without tscs). participants in both groups will undergo a baseline evaluation, then take part in 24, 1-hour training sessions at craig hospital. after the 24 sessions have concluded, participants will undergo a post-treatment evaluation as well as a follow-up evaluation four weeks after training is completed. researchers will compare the two groups by evaluating the following areas: * walking ability and speed * lower extremity strength, activation, and spasticity * trunk control * bowel and bladder function


Eligibility criteria:
inclusion criteria: * \< 12 months post traumatic isci c4-t10 with signs of upper motor neuron injury * ais c or d classification * 18 years and older * height 5'0" to 6'4" * weight 220lbs or less * sufficient upper extremity strength to manage a stability aide * medical clearance for high intensity gait training * walking \<1.46 m/s * intact skin in on pelvis, lower extremities and back * passive range of motion at shoulders, trunk, hips, knees \& ankles within functional limits exclusion criteria: * unstable or symptomatic cardiac or respiratory issues * recent history of fracture, contractures, pressure injury, deep vein thrombosis, or other infection that might interfere with participation in study * received botox injections to the lower extremities within the last six months * pregnancy * cauda equina injury * any other issue that in the opinion of the investigator would impact study participation * non-english speaking
measurement of ocular tensional fluctuation by triggerfish lens before and after cataract surgery in patients with exfoliative glaucoma

Conditions: Cataract; Exfoliative Glaucoma

Summary: glaucoma is a very frequent disease in brittany. in glaucoma the retinal ganglion cells and their axons slowly die with visible changes at the optic nerve head (cupping). without early diagnosis and effective treatment or with delayed treatment decrease of visual acuity or blindness become. in secondary pseudoexfoliation glaucoma grayish-white deposits of abnormal proteins are found on all surfaces of eye irrigated by the aqueous humor. the deposits of pex material inside the trabecular meshwork decrease aqueous humour outflow and the intraocular pression raise. the exfoliation material is found on the surface of the lens capsule with frequent developement of nuclear cataract . after cataract surgery the intra ocular pressure (iop) decrease. some recent study have found decreasing ocular volume variation associated to iop fluctuation in night after cataract surgery in normal pressure glaucoma patients. in our study we want see if it's the same thing in pseudoexfoliation glaucoma patients.


Eligibility criteria:
inclusion criteria: * adult * exfoliative glaucoma * patient who need cataract surgery * patient agree with study exclusion criteria: * monophtalm patient * patient with bleb after glaucoma surgery * terminal glaucoma * herpes * one year control impossible

Keywords: exfoliative glaucoma cataract ocular pressure
a study of the combination of anti-pd-1 ak105 and anlotinib in first-line hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: this is a multi-center,open-label study to evaluate the efficacy and safety of anti-pd-1 antibody ak105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * signed written informed consent form voluntarily. * male or female，age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the icf. * expected life expectance ≥ 3 months. * eastern cooperative oncology group (ecog) performance score 0 or 1. * confirmation either by histology unresectable hepatocellular carcinoma.. * bclc stage c, and non-resectable bclc stage b . * no prior systemic therapy for hcc. * child-pugh class a and b (≤7 points). * at least one measurable lesion according to recist criteria. * adequate hematologic and end-organ function. * for women of childbearing potential: agreement to remain abstinent; for men: agreement to remain abstinent. exclusion criteria: * prior treatment with anti-pd1, anti-pd-l1 or anti-ctla-4 antibody therapy. * active ongoing infection requiring therapy. * history of severe hypersensitivity reaction to another monoclonal antibody. * received any live attenuated vaccine within the last 30 days. * other malignancy requiring treatment in the prior 5 years with the exception of locally treated squamous or basal cell carcinoma. * pregnant, breast feeding, or planning to become pregnant. * active or prior documented autoimmune or inflammatory disease with some exceptions. * central nervous system metastases and/or carcinomatous meningitis. * medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication. * co-infection of hbv and hcv. * inadequately controlled arterial hypertension.

Keywords: vegf anti-pd-1 tyrosine kinase inhibitor (tki) angiogenesis-related kinases
does fish oil prevent depression in pregnancy and postpartum?

Conditions: Depression

Summary: this study is designed to test whether an alternative medicine treatment, fish oil, will prevent depressive symptoms in pregnant and postpartum women who have been found to be at risk for depression. epidemiologists have observed that people who live in countries where people on average eat a diet high in fish have a lower risk of depression than people who live in populations that eat less fish. postpartum depression is also less common in these countries. the omega-3 fatty acids found in fish oil are thought to be responsible for this beneficial effect of eating fish. the two major omega-3 fatty acids found in fish are eicosapentaenoic acid (epa) and docosahexaenoic acid (dha). dha is an essential building block of the brain and nerve tissue. epa may act to optimize the electrical signals between nerve cells and brain cells and may help the immune system to function well. some researchers have treated people who are already suffering from depression with fish oil. some of these studies have shown a benefit for the fish oil treatment and others have not. these studies have tested epa and dha alone and in various combinations. currently, it is not known whether epa or dha is more effective in preventing and treating depression. some of the researchers involved in this study have learned how to identify mothers who are most at risk for developing depression during and after pregnancy. this study is designed to learn whether epa-rich and dha-rich fish oil supplements will prevent depressive symptoms in women who are at risk to develop depression.


Eligibility criteria:
inclusion criteria: * women who are more than 12 weeks pregnant but less than 20 weeks pregnant * women who are found to be at risk for depression * women who have been treated for depression in the past * women with depression after a previous pregnancy * women planning to deliver at university of michigan hospital exclusion criteria: * women who have major depression or other psychiatric disorders (current substance abuse, schizophrenia, bipolar disorder) at the time of screening * women who are currently taking anti-depressant or other psychiatric medications * women who routinely eat more than 2 fish meals per week * women on anticoagulants (blood thinners) * women currently taking omega-3 fatty acid dietary supplements (fish oil, flaxseed oil or cod liver oil) * women with bleeding disorders such as von willebrand's disease * women under the age of 18 * women with a multiple gestation (twins, for example) * women planning to deliver at another hospital * women planning to move away before 6 weeks after delivery
management of human immunodeficiency virus 1 (hiv-1) participants treated with antiretroviral (arv) combination therapy including raltegravir (mk-0518-138)

Conditions: HIV Infections

Summary: to evaluate the management of hiv-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of france.


Eligibility criteria:
inclusion criteria: * participant infected with hiv-1. * participant for whom raltegravir therapy has been decided and started less than 30 days prior to inclusion in the study. * participant who has received oral and written information about the study and who has agreed to the computer processing of his/her personal data. exclusion criteria: * participant taking part in a clinical trial to assess raltegravir. * participant in whom raltegravir treatment was started more than 30 days ago.

Keywords: hiv
the effect of intravenous lipids on lung function in acute respiratory distress syndrome (ards)

Conditions: Acute Respiratory Distress Syndrome

Summary: the purpose of this study is to evaluate the effects of nutritional supplementation with omega-9 "olive-oil" and omega-6 "soybean oil" based lipid emulsions in the acute respiratory distress syndrome (ards). the investigators hypothesize that these specific lipids in combination will immunomodulate the inflammatory reaction that occurs in the lungs of ards subjects. this concept is known as "pharmaconutrition." these lipids will be given intravenously so as to assure administration and only as a supplement to enteral nutrition which all subjects will also receive. the omega-9 will be compared to the omega-6 formulation which is the only fda approved formulation of use in the united states since its development in 1961 by fresenius-kabi, bad homburg, germany. the investigators plan to perform a bronchoscopy with lavage within 24 hours of enrollment, begin the lipid administration and continue it for 96 hours after which time the investigators will repeat bronchoscopy with lavage to assess changes. the lipid administration will cease following the second bronchoscopy. the fluid obtained from lavage combined with serum samples obtained at the time of bronchoscopy will be analyzed for inflammatory mediators and cell counts. clinical data tracing will include but not be limited to: ventilator days, nutritional status, icu time, oxygenation and lung compliance, and 30-day mortality.


Eligibility criteria:
inclusion criteria: * diagnosed with predisposing condition causing ards * are mechanically ventilated through an endotracheal tube * have enteral feeding access * have central venous access * have a pao2:fio2 ratio of less than 200 * have bilateral pulmonary infiltrates on chest x-ray exclusion criteria: * sedation requiring the use of diprivan (after enrollment) * a clinical diagnosis of left ventricular failure * lung cancer * hematologic malignancy * severe dyslipidemia * condition precluding bronchoscopy including inability to maintain oxygen saturations greater than 90% per pulse oximetry despite conventional mechanical ventilation * severe immunosuppression * use of nsaids within previous 24 hours * hiv positive * pregnancy * hypersensitivity to egg or soybean oil * active myocardial infarction * acute pancreatitis if complicated by hypertriglyceridemia * severe sepsis with 2 or more organ failures

Keywords: ards parenteral pharmaconutrition
a pharmacokinetic and bioavailability study of mannitol for inhalation using normal subjects

Conditions: Healthy Volunteers

Summary: the study has an open-label, randomized, crossover design, in which each subject will receive mannitol powder for inhalation using a dry powder inhaler with and without premedication with a bronchodilator, mannitol powder for inhalation in capsules administered orally, and mannitol in a commercial formulation designed for intravenous use.


Eligibility criteria:
inclusion criteria: * subject has signed a written informed consent form. * subject is a normal male volunteer between 18 and 65 years of age. * subject is willing to comply with the procedures of the study and to remain in the clinical unit for the scheduled visits. * subject is willing to abstain from chewing gum for the duration of the study. exclusion criteria: * subject has asthma or other disease affecting the lungs or airways. * subject has a history indicating possible airway hyperresponsiveness. * subject is allergic to mannitol or gelatin or a known intolerance to intravenous mannitol. * subject uses inhaled drugs (legal or illegal). * subject uses oral bronchodilator drugs. * subject has celiac disease, crohn's disease or other disease affecting intestinal absorption. * subject has renal impairment or other condition that would affect urine collection. * subject's weight deviates by more than 15% from the ideal weight listed for his height in the metropolitan life table. * subject is a smoker. * subject has participated in another clinical trial within the past 30 days. * subject has used chewing gum within the past 72 hours. * subject needs to use bisphosphonates, non-steroidal anti-inflammatory agents, or other drugs known to affect intestinal permeability on a chronic basis. * subject has used non-steroidal anti-inflammatory agents within the past 72 hours
hypid (pulmonary hypertension in interstitial lung disease) extension

Conditions: Pulmonary Arterial Hypertension; Diffuse Interstitial Lung Disease

Summary: hypid-2 study is an extension of hypid study (nct01443598) : hypid-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. it concerns only incident patients (i.e patients included within 6 months after ph diagnosis) whereas hypid concerned prevalent and incident cases. the primary aim is the same than hypid : identify prognostic factors

pre capillary pulmonary hypertension (ph) may be present in patients with diffuse interstitial lung disease. in this context, ph represents an important factor of morbidity and mortality for these patients. as in hypid, the main purpose of hypid-2 is to determine predictive factors of mortality within this cohort of incident patients (i.e patients included within 6 months after ph diagnosis). in order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of incident patients. each incident patient will be followed during 2 years at least.

Eligibility criteria:
inclusion criteria: patients newly diagnosed with: * pre capillary pulmonary hypertension at right heart sided catheterization with: mpap \> or = 25 mmhg, pcwp \< or = 15 mmhg * interstitial lung disease with diffuse infiltrative opacities on chest ct scan exclusion criteria: * pulmonary hypertension related to a thromboembolic disease * respiratory disease other than diffuse interstitial lung disease * any etiological factor of pulmonary arterial hypertension based on nice 2013 classification other than diffuse interstitial lung disease * any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency

Keywords: pulmonary arterial hypertension interstitial lung disease at hrct
intra-pocket application of tea tree oil gel in the treatment of stage-2 periodontitis

Conditions: Periodontitis

Summary: this study aimed to assess clinically and biochemically the effect of intrapocket application of tea tree oil (tto) gel adjunctive to srp in the management of stage 2(moderate) periodontitis and to correlate the biochemical levels with clinical response.

a randomized, controlled clinical trial included thirty patients with stage 2 periodontitis. they were equally divided into two groups: group 1 (control group) treated with scaling and root planning (srp) alone and group 2 (test group) managed by srp and locally delivered 5% tea tree oil (tto) gel.

Eligibility criteria:
inclusion criteria: * patients diagnosed with stage 2,grade b periodontitis according to the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. * patients with cal 3-4 mm , bop and radiographic horizontal bone loss related to the coronal third of the root (15%-33%). * patients with no teeth loss due to periodontitis. * patients with radiographic bone loss/age % of 0.25-1 %. * patients who could maintain an o'leary plaque index ≤10 proceeded into the study. exclusion criteria: * patients with cal caused by non periodontal causes. * patients with grade c periodontitis. * patients having any systemic disease that may affect the treatment outcomes * smokers. * pregnant females. * patients receiving contraindicated medications, chemotherapy, or radiotherapy in the previous year.
treatment of microscopic colitis

Conditions: Colitis

Summary: the study compares the effect of budesonide, bismuth and fiber in patients with microscopic colitis

this randomized, controlled, open study compares the effects of 8 weeks' treatment with budesonide, bismuth and fiber on symptoms and histological findings in patients with microscopic colitis (both collagenous colitis and lymphocytic colitis).

Eligibility criteria:
inclusion criteria: * microscopic colitis verified with biopsies from the colon * symptoms to such an extent that treatment is indicated * age \> 17 years * informed consent exclusion criteria: * previous treatment with any of the investigational drugs * patients treated with ketoconazole * pregnant and breast-feeding females

Keywords: microscopic colitis drug treatment diarrhoea
magnetic resonance imaging (mri) follow-up of macrophagic infiltration in ms patients treated with tysabri

Conditions: Multiple Sclerosis

Summary: to evaluate the diagnosis value of mri and positon emission tomography (pet) scan for studying macrophagic infiltration and other brain modification in multiple sclerosis (ms) patients treated with natalizumab (tysabri).


Eligibility criteria:
inclusion criteria: * patients diagnosed with ms * treatment with tysabri planned exclusion criteria: * allergy to tysabri or mri contrast products * pregnancy

Keywords: mri, pet scan
a study of erlotinib (tarceva) in participants with non-small cell lung cancer (nsclc)

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this study will assess potentially predictive markers of efficacy in participants with nsclc receiving oral erlotinib (tarceva) therapy. the anticipated time on study treatment is until disease progression, unacceptable toxicity or death.


Eligibility criteria:
inclusion criteria: * advanced nsclc * tumor accessible for biopsy by bronchoscopy * disease progression following course of standard chemotherapy, or participants unwilling/unable to undergo chemotherapy exclusion criteria: * unstable systemic disease * any other malignancies in the last 5 years * brain metastases * previous treatment with therapy acting on the epidermal growth factor receptor (egfr) axis